$Treatment outcomes of triple class refractory multiple myeloma: a benchmark for new therapies$

Treatment outcomes of triple class refractory multiple myeloma: a benchmark for new therapies

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Leukemia 2022-03, Vol.36 (3), p.877-880
Hauptverfasser:	Bal, Susan, Malek, Ehsan, Kansagra, Ankit, Usmani, Saad Z., Vij, Ravi, Godby, Kelly N., Cornell, Robert F., Kang, Yubin, Umyarova, Elvira, Giri, Smith, Chhabra, Saurabh, Liedtke, Michaela, Callander, Natalie S., Hari, Parameswaran, Kumar, Shaji, Costa, Luciano J.
Format:	Artikel
Sprache:	eng
Schlagworte:	692/308/174 692/699/1541/1990/804 Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols - therapeutic use Benchmarking Cancer Research Clinical outcomes Critical Care Medicine Female Hematology Humans Intensive Internal Medicine Letter Leukemia Male Medicine Medicine & Public Health Middle Aged Monoclonal antibodies Multiple myeloma Multiple Myeloma - drug therapy Oncology Progression-Free Survival Regulatory approval Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!